Macular Degeneration Medications

Cimerli (ranibizumab-eqrn) is used to treat macular degeneration. Cimerli is a biosimilar for lucentis (ranibizumab). Biosimilars are biologic drugs that are similar to the original medication with no meaningful differences in effectiveness or safety. Cimerli may be covered by your Medicare or insurance plan.

Byooviz (ranibizumab-nuna) is used to treat macular degeneration. Byooviz is a biosimilar for lucentis (ranibizumab). Biosimilars are biologic drugs that are similar to the original medication with no meaningful differences in effectiveness or safety. Byooviz may be covered by your Medicare or insurance plan.

Pavblu is part of the VEGF Antibodies class and treats Macular Degeneration. VEGF antibodies are used to treat colon cancer, lung cancer, renal cancer, brain tumors, thyroid cancer, macular degeneration, and vitreomacular adhesion. They work by slowing down cancer cell growth to prevent it from spreading. Pavblu is only available as a brand name drug.

Vabysmo (faricimab) is used to treat macular degeneration, diabetic macular edema, and macular edema following retinal vein occlusion. There are currently no generic alternatives to Vabysmo. It may be covered by your Medicare or insurance plan, but some pharmacy coupons or cash prices could help offset the cost.

AVACINCAPTAD PEGOL treats macular degeneration, a condition that can cause vision loss. It works by helping to slow changes in vision.

PEGCETACOPLAN treats macular degeneration, a condition that can cause vision loss. It works by helping to slow changes in vision.

BROLUCIZUMAB treats macular degeneration and macular edema. It works by slowing the growth of abnormal new blood vessels in the eye. It also reduces the amount of fluid that leaks from these blood vessels. This helps maintain vision. It is a monoclonal antibody.

RANIBIZUMAB treats eye conditions, such as macular degeneration, macular edema, and retinopathy. It works by slowing the growth of abnormal new blood vessels in the eye. It also reduces the amount of fluid that leaks from these blood vessels. This helps maintain vision. It is a monoclonal antibody.

AFLIBERCEPT treats eye conditions, such as macular degeneration, macular edema, and retinopathy. It works by slowing the growth of abnormal new blood vessels in the eye. It also reduces the amount of fluid that leaks from these blood vessels. This helps maintain vision.

AFLIBERCEPT treats eye conditions, such as macular degeneration, macular edema, and retinopathy. It works by slowing the growth of abnormal new blood vessels in the eye. It also reduces the amount of fluid that leaks from these blood vessels. This helps maintain vision.

FLUOCINOLONE treats eye inflammation and swelling. It is prescribed when other medications have not worked well enough. It works by decreasing inflammation in the eye. It belongs to a group of medications called steroids.

Lucentis (ranibizumab) is used to treat macular degeneration. Lucentis is also available as a biosimilar. Biosimilars are biologic drugs that are similar to the original medication with no meaningful differences in effectiveness or safety. The currently approved biosimliars for Lucentis are cimerli (ranibizumab-eqrn) and byooviz (ranibizumab-nuna). Lucentis may be covered by your Medicare or insurance plan.

VERTEPORFIN treats choroidal neovascularization, the growth of abnormal blood vessels in the eye that can cause vision loss. It is used in combination with ultraviolet light therapy. It works by closing up leaky blood vessels. This helps maintain vision.